180 related articles for article (PubMed ID: 38733183)
21. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases.
Lemoinne S; Friedman SL
Curr Opin Pharmacol; 2019 Dec; 49():60-70. PubMed ID: 31590120
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
[TBL] [Abstract][Full Text] [Related]
23. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
Boursier J; de Ledinghen V; Leroy V; Anty R; Francque S; Salmon D; Lannes A; Bertrais S; Oberti F; Fouchard-Hubert I; Calès P
J Hepatol; 2017 Jun; 66(6):1158-1165. PubMed ID: 28088581
[TBL] [Abstract][Full Text] [Related]
24. Liver fibrosis: the 2017 state of art.
Caviglia GP; Rosso C; Fagoonee S; Saracco GM; Pellicano R
Panminerva Med; 2017 Dec; 59(4):320-331. PubMed ID: 28880053
[TBL] [Abstract][Full Text] [Related]
25. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
Nishikawa K; Osawa Y; Kimura K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308992
[TBL] [Abstract][Full Text] [Related]
26. Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver disease.
Xu F; Zhang H; Chen J; Zhan J; Liu P; Liu W; Qi S; Mu Y
J Ethnopharmacol; 2024 Mar; 321():117514. PubMed ID: 38042388
[TBL] [Abstract][Full Text] [Related]
27. Peptide-Based Nanoarchitectonics for the Treatment of Liver Fibrosis.
Li B; Huang Y; Zou Q
Chembiochem; 2023 May; 24(9):e202300002. PubMed ID: 36781383
[TBL] [Abstract][Full Text] [Related]
28. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.
Traber PG; Chou H; Zomer E; Hong F; Klyosov A; Fiel MI; Friedman SL
PLoS One; 2013; 8(10):e75361. PubMed ID: 24130706
[TBL] [Abstract][Full Text] [Related]
29. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.
Sepulveda-Crespo D; Resino S; Martinez I
Drugs; 2021 Mar; 81(4):419-443. PubMed ID: 33400242
[TBL] [Abstract][Full Text] [Related]
30. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.
Mohammed OS; Attia HG; Mohamed BMSA; Elbaset MA; Fayed HM
J Pharm Pharm Sci; 2023; 26():11808. PubMed ID: 38022905
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic targets in liver fibrosis.
Fallowfield JA
Am J Physiol Gastrointest Liver Physiol; 2011 May; 300(5):G709-15. PubMed ID: 21233278
[TBL] [Abstract][Full Text] [Related]
32. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Lefere S; Devisscher L; Tacke F
Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
[No Abstract] [Full Text] [Related]
33. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis.
Peng W; Cheng S; Bao Z; Wang Y; Zhou W; Wang J; Yang Q; Chen C; Wang W
Biomed Pharmacother; 2021 May; 137():111342. PubMed ID: 33581652
[TBL] [Abstract][Full Text] [Related]
34. [Research progress and prospect of liver cirrhosis].
Xu JH; Yu YY; Xu XY
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):108-110. PubMed ID: 33685076
[TBL] [Abstract][Full Text] [Related]
35. Nanostructure-based therapies for liver fibrosis.
Zugravu Pop DD; Mitrea DR; Suciu S; Clichici SV
J Physiol Pharmacol; 2020 Dec; 71(6):. PubMed ID: 33727424
[TBL] [Abstract][Full Text] [Related]
36. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
Zhang CY; Yuan WG; He P; Lei JH; Wang CX
World J Gastroenterol; 2016 Dec; 22(48):10512-10522. PubMed ID: 28082803
[TBL] [Abstract][Full Text] [Related]
37. Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis.
Chen Z; Jain A; Liu H; Zhao Z; Cheng K
J Pharmacol Exp Ther; 2019 Sep; 370(3):695-702. PubMed ID: 30886124
[TBL] [Abstract][Full Text] [Related]
38. [Pathogenesis and methods evaluation of liver fibrosis in HIV/HCV co-infection].
Inglot M; Szymczak A; Hałoń A
Przegl Epidemiol; 2010; 64(4):465-71. PubMed ID: 21473059
[TBL] [Abstract][Full Text] [Related]
39. Methoxyeugenol deactivates hepatic stellate cells and attenuates liver fibrosis and inflammation through a PPAR-ɣ and NF-kB mechanism.
de Souza Basso B; Haute GV; Ortega-Ribera M; Luft C; Antunes GL; Bastos MS; Carlessi LP; Levorse VG; Cassel E; Donadio MVF; Santarém ER; Gracia-Sancho J; Rodrigues de Oliveira J
J Ethnopharmacol; 2021 Nov; 280():114433. PubMed ID: 34280502
[TBL] [Abstract][Full Text] [Related]
40. Development and Regression of Cirrhosis.
Saffioti F; Pinzani M
Dig Dis; 2016; 34(4):374-81. PubMed ID: 27170391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
